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Abstract
Objective: This study aimed to determine the etiologic factors of acquired methemoglobinemia in 
infants younger than three months in our region. 
Material and Methods: This study was carried out retrospectively in infants with methemoglobinemia 
admitted to Karadeniz Technical University, Pediatric Clinic, during the period 2000-2009. Infants 
with methemoglobinemia were identified according to the medical records or ICD-10 code. 
Results: Nine infants with acquired methemoglobinemia (8 male, 1 female) were included in the study. 
Seven cases were associated with the use of prilocaine for circumcision, one case with the use of prilocaine-
lidocaine for local pain therapy, and one case with neonatal sepsis caused by Staphylococcus aureus.
Conclusion: Prilocaine should not be used in infants less than three months of age because of the risk 
of  methemoglobinemia.  Ascorbic  acid  is  an  effective  therapy  if  methylene  blue  is  not  obtained.   
It should not be forgotten that sepsis caused by S. aureus may cause methemoglobinemia in infants.
(Turk J Hematol 2011; 28: 131-4)
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Özet
Amaç: Bölgemizde üç aydan küçük bebeklerde meydana gelen akkiz methemoglobinemilerin etiyolo-
jisini araştırmak.
Yöntem ve Gereçler: Bu çalışma, 2000-2009 yılları arasında pediatri kliniğine başvuran ve ICD-10 
koduna veya hasta kayıt defterine göre akkiz methemoglobinemi tanısı alan hastaların kayıtlarının 
retrospektif incelenmesi ile gerçekleştirildi. 
Bulgular: Sekizi erkek olmak üzere, dokuz akkiz methemoglobinemili infant çalışmaya alındı. Yedi 
vaka; sünnet için prilokain kullanımı ile ilişkili iken, bir vaka; lokal anestezi için kullanılan prilokain–
lidokain ile ve diğer vaka ise; Staphylococcus aureus sepsisi ile ilişkili idi.
Sonuç: Üç aydan küçük infantlarda prilokain methemoglobinemi riski nedeniyle kullanılmamalıdır ve 
metilen mavisi elde edilemediği durumlarda vitamin C effektif bir tedavi şeklidir. Staphylococcus 
aureus’a bağlı sepsisin infantlarda methemoglobinemiye neden olabileceği unutulmamalıdır. 
(Turk J Hematol 2011; 28: 131-4)
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Geliş tarihi: 8 Nisan 2010     Kabul tarihi: 11 Mayıs 2010 Introduction
Methemoglobinemia  is  an  uncommon  cause  of 
cyanosis. It should be suspected in an infant with cya-
nosis  who  has  no  respiratory  distress  or  cyanotic 
congenital heart disease. Cyanosis is recognized in 
patients  with  methemoglobin  (MetHb)  concentra-
tions higher than 1.5 g/dl [1,2]. It develops due to both 
acquired and congenital factors. Congenital causes of 
methemoglobinemia  are  NADH-cytochrome  b5 
reductase and NADPH-MetHb reductase deficiencies 
or  presence  of  abnormal  Hb  such  as  Hb  M  [2]. 
Acquired  methemoglobinemia  is  caused  by  some 
drugs such as local anesthetics, some foods or water 
containing high levels of nitrate, gastrointestinal infec-
tion, and sepsis [2-4]. Most of the acquired methemo-
globinemia cases in clinical practice are due to local 
anesthetics. In this report, nine infants with methe-
moglobinemia are presented and the etiologic factors 
are discussed.
Materials and Methods
This study was carried out retrospectively in infants 
with  methemoglobinemia  admitted  to  Karadeniz 
Technical University, Pediatric Clinic, during the peri-
od 2000-2009. Infants with methemoglobinemia were 
identified according to the medical records or ICD-10 
code. Medical charts of all infants with methemoglo-
binemia were reviewed for birth weight (g), gender, 
postnatal age, Hb levels, presenting symptoms, etio-
logic causes, type of feeding, MetHb levels, treatment, 
recovery time of methemoglobinemia, and glucose-
6-phosphate  dehydrogenase  (G6PD)  deficiency. 
Blood  MetHb  levels  were  measured  by  using  a 
Rapidlab®  1200  Blood  Gas  Analyzer  (Siemens 
Healthcare  Diagnostics)  with  spectrophotometric 
method. Blood MetHb levels were measured at four-
hour intervals. Sepsis was considered in infants hav-
ing two or more of the following criteria associated 
with positive blood culture: (a) fever or hypothermia, 
(b)  tachycardia,  (c)  tachypnea  or  apnea,  and  (d) 
abnormal white blood cells or increase in band/total 
neutrophils. Written informed consent was obtained 
from the patients’ family.
Results
Nine infants with methemoglobinemia (8 male, 1 
female)  were  included  in  the  study.  Mean  birth 
weight  and  postnatal  age  were  3655±270  (3300-
4100) g and 33.7±16.6 d (5-60) days, respectively. 
Cyanosis was present in all infants, fever in three 
(33%), and hypotonia and refusal to breast-feed in 
two (22%). Mean percentage of MetHb levels of the 
infants was 28.8±9.8 (14.7-44%). Seven cases were 
associated with the use of a local anesthetic agent 
(prilocaine; Citanest® 0.5%) for circumcision. The 
applied prilocaine doses were not determined. One 
case was associated with the use of prilocaine–lido-
caine  (EMLA®,  5%,  Astra  Zeneca)  for  local  pain 
therapy after scalding to 3% of the body surface, and 
three cases were associated with neonatal sepsis. 
No phenol disinfectant was used for floor cleaning 
in the hospital during this period.
Staphylococcus hominis was grown in blood cul-
tures of two infants (Case 3 and Case 5) associated 
with the use of prilocaine. Staphylococcus aureus 
was grown in the blood culture of Case 6. Acute 
phase reactants (procalcitonin and C-reactive pro-
tein [CRP]) were positive in these neonates, and 
they met sepsis criteria. They were treated with van-
comycin. All of the neonates were receiving only 
breast milk. Their mothers denied the use of any 
medications  and  consumption  of  any  foods  con-
taining a high nitrate level.
Two neonates were treated with methylene blue 
(1-2  mg/kg)  intravenously,  and  the  others  were 
treated  with  vitamin  C  (300  mg)  intravenously 
because  methylene  blue  was  not  obtained. 
Repeated doses were not necessary. Mean recov-
ery  time  was  10.2±3.5  [4-16]  hours.  The  plasma 
G6PD  levels  were  normal  in  all  neonates. 
Cytochrome  b5  reductase  activity  could  not  be 
measured in the neonates because of the lack of 
technical facilities. Demographic, clinic and labora-
tory characteristics of the neonates associated with 
methemoglobinemia are shown in Table 1.
Discussion
Methemoglobinemia is characterized by oxida-
tion of the iron in Hb from a ferrous (Fe++) to a 
ferric (Fe+++) form. Methemoglobinemia occurs 
in healthy persons but the intraerythrocytic MetHb-
reducing system maintains its concentration at less 
than 1% of the total Hb [5]. There are two MetHb-
reducing systems (NADH-cytochrome b5 reductase 
and  NADPH-MetHb  reductase)  in  erythrocytes. 
Under physiological conditions, NADH-cytochrome 
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95-99% of the MetHb [5]. NADPH-MetHb reductase 
usually plays only a minor role in the removal of 
MetHb. This enzyme system utilizes NADPH, which 
is produced by G6PD. NADPH-MetHb reductase has 
a more important role in MetHb regulation in infants 
with  cytochrome  b5  reductase  deficiency.  MetHb 
has an increased affinity for oxygen, and causes a 
leftward shift in the oxygen dissociation curve, and 
hypoxemia  and  lactic  acidosis  develop  [1,2,6].  If 
MetHb  level  is  higher  than  10%,  cyanosis  occurs, 
and a MetHb level of 70% is lethal. Cyanosis was 
observed  in  all  of  our  infants  and  all  of  them 
improved after the appropriate treatments.
Prilocaine is widely used in children and adults 
as  a  local  anesthetic  agent,  and  its  metabolite 
o-toluidine  can  cause  methemoglobinemia.  The 
dose of prilocaine and the age of the infant are the 
most important predictive factors for higher MetHb 
formation [7]. Infants are more vulnerable to met-
hemoglobinemia because they have higher gastric 
pH  than  that  in  older  children,  and  this  causes 
greater bacterial proliferation of the intestinal flora 
that can convert the ingested nitrate to nitrite [6]. 
Fetal Hb is the predominant form of Hb in infants, 
and is oxidized more readily to MetHb by nitrite [6]. 
The  cytochrome  b5  MetHb  reductase  activity  is 
reduced 50% in infants compared with older chil-
dren and adults [6,8]. Guay [9] suggested that prilo-
caine should not be used in children younger than 
six  months  and  the  doses  should  not  exceed  2.5 
mg/kg  in  children  older  than  six  months.  In  this 
study,  MetHb  in  seven  neonates  was  associated 
with the use of prilocaine for circumcision, and all 
of them were younger than two months. 
Symptomatic  methemoglobinemia  may  develop 
due to the application of EMLA® on the injured skin 
[10].  Methemoglobinemia  was  observed  in  Case  5 
due to the application of EMLA® for local pain therapy. 
Blood MetHb levels may be increased in patients 
with  sepsis  [3,4].  Large  amounts  of  nitric  oxide 
(NO)  are  released  in  sepsis  and  septic  shock 
[11,12]. NO interacts with Hb, and leads to methe-
moglobinemia [13]. S. aureus has a respiratory type 
of nitrate reductase enzyme system. This enzyme 
system may convert nitrate to nitrite, and methemo-
globinemia may develop [14]. Vancomycin-related 
methemoglobinemia has not been reported in the 
literature. We believe that methemoglobinemia was 
related  with  sepsis  rather  than  vancomycin  [15]; 
Table 1. Demographic, clinic and laboratory characteristics of the patients with methemoglobinemia
  Birth   Postnatal  Gender  Complaints  Hb  MetHb  Etiologic  Treatment  Recovery  G6PD
  Weight (g)  age (day)      (gr/dL)  (%)  causes    time (h)  level
                  (MetHb <5%) 
Case 1  4000  45   Male  Cyanosis  10.9  24.1  Prilocaine  300 mg C vit  8  Normal
Case 2  3700  60   Male  Cyanosis  11.2  39.9  Prilocaine  300 mg C vit  12  Normal
Case 3  4100  5   Male  Cyanosis, hypotonia,   14.7  14.7  Prilocaine  300 mg C vit  4  Normal
        fever, refusal to       Sepsis  +Antibiotics
        breast-feed        caused by
              S. hominis??     l
Case 4  3300  22   Male  Cyanosis  8.8  33.7  Prilocaine  300 mg C vit  12  Normal
Case 5  3600  35  Male  Cyanosis, fever,  13.5  19.0  Prilocaine-  300 mg C vit  8  Normal
        refusal to      lidocaine  +Antibiotics
        breast-feed      Sepsis 
              caused by
              S. hominis??    
Case 6  3300  17   Female  Fever, hypotonia,   13.5  20.9  Sepsis   300 mg C vit  8  Normal
        cyanosis      caused by  +Antibiotics
              S. aureus     
Case 7  3600  45   Male  Cyanosis  10.5  44  Prilocaine  Methylene   16  Normal
                blue (1 mg/kg) 
Case 8  3700  37  Male  Cyanosis  11.5  30.4  Prilocaine  300 mg C vit  12  Normal
Case 9  3600  48  Male  Cyanosis  11.8  26.8  Prilocaine  Methylene   12  Normal
                blue (1 mg/kg) 
G6PD: Glucose-6-phosphate dehydrogenase, Hb: Hemoglobin, MetHb: Methemoglobin
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vancomycin could not be completely ruled out. As 
far  as  we  know,  S.  hominis  does  not  have  this 
enzyme  system.  Therefore,  we  believe  that  prilo-
caine was responsible for the methemoglobinemia 
in the neonates (Case 3-Case 5). 
Methylene  blue  accelerates  the  NADPH-
dependent  MetHb  reduction  pathway  [16]. 
Methylene blue was given (1-2 mg/kg) in only two 
infants because it was not obtained for the others. 
Ascorbic acid directly reduces MetHb and it is effec-
tive  when  used  alone  [17].  Intravenous  300  mg 
ascorbic  acid  was  used  in  seven  cases,  and  all 
cases recovered between 8-16 hours. 
Prilocaine should not be used in infants less than 
three months of age because of the risk of methe-
moglobinemia. Ascorbic acid is an effective therapy 
if methylene blue is not obtained. It should not be 
forgotten that S. aureus may cause methemoglobin-
emia in infants. 
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